Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 4/2012

01-08-2012 | Urology – Original Paper

Occurrence of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome in patients with abdominal obesity. Where is a sufficient level of testosterone?

Authors: Juraj Fillo, Jan Breza, Michaela Levčíkova, Jan Luha, Anna Vachulova, Štefan Durdík, Peter Labaš

Published in: International Urology and Nephrology | Issue 4/2012

Login to get access

Abstract

Aim

The aim of this study was to determine the prevalence of erectile dysfunction (ED), testosterone deficiency syndrome (TDS), and metabolic syndrome in patients with abdominal obesity (AO) and the prevalence of morbidity at different levels of testosterone (TST).

Background

Male sex hormones play an important role in ED and variety of TDS and may have influence on the development of metabolic syndrome. The number of men with AO which constitutes a serious health risk is continuously growing. Currently, there are different views that TST levels are already insufficient, and the patient should benefit from treatment.

Objectives

This study examined the association between ED, testosterone level and metabolic syndrome in men with AO.

Design, setting, and participants

The study was carried out in an outpatient urology center of Urology Clinic and Obesity Center of the Clinic of Internal Medicine. There were 167 participants—men with AO which were examined as part of preventive examination.

Methods

Hormonal, a complete urological and internal evaluation was carried out in every patient.

Results and limitations

We found some degree of ED in 73% (122/167) in men with AO. The TST levels below 14 nmol/l had of these 122 patients 84 patients (68.9%) and 49 patients (40.2%) below 10 nmol/l. In this group of patients, we found 103/167 patients (61.7%) with metabolic syndrome. When we compared TST level and morbidity, we found significantly more patients with diabetes mellitus (DM), hypertension and dyslipidemia in group with TST below 10 nmol/l. We also found difference in the levels of HDL cholesterol and triglycerides in the group of patients with TST 10–14 and over 14 nmol/l.

Conclusion

Patients over 40 years of age with AO and ED should also be examined for TDS and metabolic syndrome. In this group of patients we found that 113/167 patients (67.6%) had total TST below 14 nmol/l, and sufficient level of TST seems to be above this level.
Literature
1.
Nicolsi A, Moreira ED Jr, Shirai M, Bin Mohd Tambi MI, Glasser DB (2003) Epidemiology of erectile dysfunction in four countries: cross-national study of prevalence and correlates of erectile dysfunction. Urology 61:201–206CrossRef
2.
Melman A, Gingel JC (1999) The epidemiology and pathophysiology of erectile dysfunction. J Urol 161:5–11PubMedCrossRef
3.
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinley IB (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151(1):54–61PubMed
4.
Parazzini F, Menchini Fabris F, Bortolotti A, Calabro A, Chatenoud L, Colli E (2003) Frequency and determinant of erectile dysfunction in Italy. Eur Urol 37:43–49CrossRef
5.
Makhsida N, Shah J, Yan G, Fish H, Shabsigh R (2005) Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 174:827–834PubMedCrossRef
6.
Kaufman JM, Vermeulen A (2005) The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocrinol Rev 26:833–876CrossRef
7.
Gooren LJ, Saad F (2006) Recent insight into androgen action on the anatomical and physiological substrate of penile erection. Asian J Androl 8:3–9PubMedCrossRef
8.
Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros J–J et al (2005) Investigation treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM and EAU recommendations. Eur Urol 48:1–4PubMedCrossRef
9.
10.
Feldman HA (2002) Age trends in the levels of serum testosterone and other hormones in the middle-aged men: longitudinal results from the Massachusetts Male Aging study. J Clin Endorcrinol Metab 87:589–591CrossRef
11.
Isidori AM, Caprio M, Strollo F et al (1999) Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgens levels. J Clin Endrocrinol Metab 84:3673–3680CrossRef
12.
Khaw K, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, Welch A, Day N (2007) Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation 116:2694–2701PubMedCrossRef
13.
Laaksonen DE, Niskanen I, Punnonen K et al (2004) Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27:1036–1041PubMedCrossRef
14.
Tsai E, Boyko EG, Leonetti DL, Fujimoto WY (2000) Low testosterone level as a predictor of increased visceral fat in Japanese-American men. Int J Obes Relat Metab disord 24:485PubMedCrossRef
15.
Makinen J, Jarvisalo J, Pollanen P, Perheentupa A, Irjala K, Kosekenvuo M, Makinen J, Huhtaniemi I, Raitakari OT (2005) Increased carotid atherosclerosis in Andropausal middle-aged men. J Am Coll Cardiol 45:1603–1608PubMedCrossRef
16.
Mulligan T, Frick MF, Zuraw QC, Stemhagen A, Mcwhirter C (2006) Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 60:762–769PubMedCrossRef
17.
Fung M, Bettencoast R, Barrett-Connor R (2004) Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study. J Am Coll Cardiol 1405–1411
18.
Corona G, Mannucci E, Schulman C, Petrone L, Mansani R, Cilotti A, Balercia G, Ghiarini V, Forti G, Maggi M (2006) Psychologic correlates of metabolic syndrome and associated sexual dysfunction. Eur Urol 50:595–604PubMedCrossRef
19.
Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB (2006) Low sex hormone binging globulin, total testosterone and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91:843–950PubMedCrossRef
20.
Khan R, Buse J, Ferranni E, Stern M (2005) The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care 28:2289–2304CrossRef
21.
Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR (2006) Low serum testosterone and mortality in male veterans. Arch Intern Med 166:1660–1665PubMedCrossRef
22.
Corona G, Mannucci E, Petrone L, Schulman C, Balercia G, Fisher AD, Chiarini V, Forti G, Maggi M (2007) A comparison of NCEP -ATPIII and IDF metabolic syndrome definitions with relation to metabolic syndrome associated sexual dysfunction. J Sex Med 4:789–796PubMedCrossRef
23.
Mäkinen JI, Perheentupa A, Irjala K, Pöllänen P, Mäkinen J, Huhtaniemi I, Raitakari OT (2008) Endogenous testosterone and serum lipids in middle-aged men. Atherosclerosis 197(2):688-693
24.
25.
Billups KL, Kaiser DR, Lelly AS, Wetterling RA, Tsai MY, Hanson N, Bank AJ (2003) Relation of C- reactive protein and other cardiovascular risk factors to penile vascular disease in men with erectile dysfunction. Int J Impot Res 15:231–236PubMedCrossRef
26.
Kolodny L (2003) Erectile dysfunction and vascular disease. What is the connection? Postrad Med 114:30–34
27.
De Angelis L, Marfella MA, Sinisclchi M, Marion L, Napppo F, Giugliano F, De Lucia D, Giugliano D (2001) Erectile and endothelial dysfunction in type II diabetes. A possible link. Diabetologia 44:1155–1160PubMedCrossRef
28.
Billups K, Bank AJ, Padma-Nathan H, Katz S, Wiliams R (2005) Erectile dysfunction is a marker for cardiovascular disease: results of the Minority Health Institute Expert Advisory Panel. J Sex Med 2:40–50PubMedCrossRef
29.
Heinemann LAJ, Zimmermann T, Vermeulen A, Thiel C, Hummel W (2001) A new aging males’ symptoms rating scale. Ageing Male 2:105–114CrossRef
30.
Rosen RC (2006) Research instruments for the diagnosis and treatment of patients with erectile dysfunction. Urology 68(sup. 3A):6–16
31.
32.
Tkáč I (2005) New recommendations from expert panel. Diagnosis and possibilities of influencing the metabolic syndrome. Curr Clin Praxis (Súčasná klin prax) 1:12–15
33.
Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Sepherd J (2003) Metabolic syndrome with and without C reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108:414–419PubMedCrossRef
34.
Lauglin GA, Barett-Connor E, Bergstrom J (2008) Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 93:68–75CrossRef
35.
Ford ES, Abbassi F, Reaver GM (2005) Prevalence of insulin resistance and the metabolic syndrome with alternative definitions of impaired fasting glucose. Atherosclerosis 181:143–148PubMedCrossRef
36.
Mokaň M, Galajda P, Pridavkova D (2006) Prevalencia diabetes mellitus a metabolického syndromu na Slovensku. Diabetes a obezita 6(12):10–17
Metadata
Title
Occurrence of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome in patients with abdominal obesity. Where is a sufficient level of testosterone?
Authors
Juraj Fillo
Jan Breza
Michaela Levčíkova
Jan Luha
Anna Vachulova
Štefan Durdík
Peter Labaš
Publication date
01-08-2012
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 4/2012
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-012-0132-1

Other articles of this Issue 4/2012

International Urology and Nephrology 4/2012 Go to the issue

Urology – Case Report

Primary adenocarcinoma of the epididymis: the therapeutic role of retroperitoneal lymphadenectomy

Urology – Original Paper

The role of free to total PSA ratio in prediction of extracapsular tumor extension and biochemical recurrence after radical prostatectomy in patients with PSA between 4 and 10 ng/ml

Urology – Case Report

Rhabdomyolysis with acute kidney injury in deceased donors is not a contraindication for kidney donation

Urology – Original Paper

Ultrasonic predictors of improved seminal parameters after bilateral laparoscopic varicocelectomy

Erratum

Erratum to: Low plasma adiponectin levels predict increased urinary albumin/creatinine ratio in type 2 diabetes patients

Nephrology – Review

Is 24,25(OH)D level really high in dialysis patients with high FGF23 levels?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits